Mandate

Vinge advised Investor in connection with the IPO of Alligator

November 23, 2016

Alligator Bioscience AB (publ) was listed on the main market of Nasdaq Stockholm with the first day of trading being 23 November 2016. The price in the initial public offering was SEK 32.50 per share, corresponding to a total value of the company’s shares of approx. SEK 2,275 million. Investor AB, through Duba AB, was one of the two selling shareholders.
 
Vinge advised Investor. The Vinge team was headed by capital markets and public M&A partner Erik Sjöman.

Related

Vinge has advised Skeptiva AB in connection with its financing round

Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026

Vinge represents Studsvik AB (publ) in the acquisition of Kärnfull Next AB

Vinge has represented Studsvik AB (publ) in connection with the acquisition of Kärnfull Next AB, a company developing methods for building small modular nuclear reactors.
March 10, 2026